nodes	percent_of_prediction	percent_of_DWPC	metapath
Letrozole—CYP19A1—uterine cancer	0.547	1	CbGaD
Letrozole—CYP2A6—Progesterone—uterine cancer	0.142	0.605	CbGbCtD
Letrozole—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0428	0.183	CbGbCtD
Letrozole—CYP3A4—Progesterone—uterine cancer	0.0283	0.121	CbGbCtD
Letrozole—CYP19A1—corpus luteum—uterine cancer	0.0147	0.52	CbGeAlD
Letrozole—CYP3A4—Etoposide—uterine cancer	0.0127	0.0542	CbGbCtD
Letrozole—CYP3A4—Doxorubicin—uterine cancer	0.00865	0.0369	CbGbCtD
Letrozole—CYP19A1—semen—uterine cancer	0.00687	0.244	CbGeAlD
Letrozole—Bifonazole—CYP19A1—uterine cancer	0.00171	1	CrCbGaD
Letrozole—CYP19A1—endometrium—uterine cancer	0.00113	0.0403	CbGeAlD
Letrozole—CYP2A6—vagina—uterine cancer	0.00108	0.0385	CbGeAlD
Letrozole—CYP19A1—uterus—uterine cancer	0.00105	0.0371	CbGeAlD
Letrozole—CYP19A1—Metabolism of steroid hormones and vitamin D—SRD5A2—uterine cancer	0.000968	0.0752	CbGpPWpGaD
Letrozole—CYP19A1—female reproductive system—uterine cancer	0.00094	0.0334	CbGeAlD
Letrozole—CYP19A1—female gonad—uterine cancer	0.000855	0.0304	CbGeAlD
Letrozole—CYP19A1—Metabolism of steroid hormones and vitamin D—STAR—uterine cancer	0.0007	0.0544	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of steroid hormones and vitamin D—AKR1B1—uterine cancer	0.0007	0.0544	CbGpPWpGaD
Letrozole—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFE2L2—uterine cancer	0.000672	0.0522	CbGpPWpGaD
Letrozole—CYP3A4—renal system—uterine cancer	0.000569	0.0202	CbGeAlD
Letrozole—CYP19A1—Endogenous sterols—CYP11A1—uterine cancer	0.000559	0.0434	CbGpPWpGaD
Letrozole—CYP19A1—lymph node—uterine cancer	0.00055	0.0195	CbGeAlD
Letrozole—CYP3A4—female reproductive system—uterine cancer	0.000456	0.0162	CbGeAlD
Letrozole—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—uterine cancer	0.000424	0.0329	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of steroid hormones and vitamin D—CYP11A1—uterine cancer	0.000419	0.0325	CbGpPWpGaD
Letrozole—CYP19A1—Ovarian Infertility Genes—MLH1—uterine cancer	0.000417	0.0324	CbGpPWpGaD
Letrozole—CYP19A1—Ovarian Infertility Genes—PGR—uterine cancer	0.000395	0.0307	CbGpPWpGaD
Letrozole—CYP2A6—Fluoropyrimidine Activity—RRM2—uterine cancer	0.000365	0.0283	CbGpPWpGaD
Letrozole—CYP19A1—Ovarian Infertility Genes—ESR2—uterine cancer	0.000348	0.027	CbGpPWpGaD
Letrozole—CYP3A4—Benzo(a)pyrene metabolism—AKR1C3—uterine cancer	0.000326	0.0254	CbGpPWpGaD
Letrozole—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.00026	0.0202	CbGpPWpGaD
Letrozole—CYP19A1—Ovarian Infertility Genes—SMAD3—uterine cancer	0.000259	0.0201	CbGpPWpGaD
Letrozole—CYP19A1—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000256	0.0199	CbGpPWpGaD
Letrozole—CYP19A1—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.00021	0.0164	CbGpPWpGaD
Letrozole—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000207	0.0161	CbGpPWpGaD
Letrozole—CYP2A6—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000204	0.0158	CbGpPWpGaD
Letrozole—CYP19A1—Metapathway biotransformation—AKR1B10—uterine cancer	0.000198	0.0154	CbGpPWpGaD
Letrozole—CYP2A6—Fluoropyrimidine Activity—MTHFR—uterine cancer	0.000184	0.0143	CbGpPWpGaD
Letrozole—CYP19A1—Metapathway biotransformation—AKR1B1—uterine cancer	0.000184	0.0143	CbGpPWpGaD
Letrozole—CYP2A6—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000168	0.013	CbGpPWpGaD
Letrozole—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—uterine cancer	0.000165	0.0128	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—MSH6—uterine cancer	0.000165	0.0128	CbGpPWpGaD
Letrozole—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000156	0.000887	CcSEcCtD
Letrozole—Mediastinal disorder—Etoposide—uterine cancer	0.000156	0.000885	CcSEcCtD
Letrozole—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000155	0.000878	CcSEcCtD
Letrozole—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000154	0.000874	CcSEcCtD
Letrozole—Alopecia—Etoposide—uterine cancer	0.000153	0.000868	CcSEcCtD
Letrozole—Vomiting—Progesterone—uterine cancer	0.000153	0.000867	CcSEcCtD
Letrozole—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000152	0.0118	CbGpPWpGaD
Letrozole—Rash—Progesterone—uterine cancer	0.000152	0.00086	CcSEcCtD
Letrozole—Dermatitis—Progesterone—uterine cancer	0.000152	0.000859	CcSEcCtD
Letrozole—Phlebitis—Doxorubicin—uterine cancer	0.000151	0.000855	CcSEcCtD
Letrozole—Headache—Progesterone—uterine cancer	0.000151	0.000855	CcSEcCtD
Letrozole—Hot flush—Epirubicin—uterine cancer	0.00015	0.000851	CcSEcCtD
Letrozole—Thrombophlebitis—Doxorubicin—uterine cancer	0.00015	0.000851	CcSEcCtD
Letrozole—CYP2A6—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.00015	0.0117	CbGpPWpGaD
Letrozole—Increased appetite—Epirubicin—uterine cancer	0.000149	0.000847	CcSEcCtD
Letrozole—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000149	0.000846	CcSEcCtD
Letrozole—Menopausal symptoms—Epirubicin—uterine cancer	0.000149	0.000843	CcSEcCtD
Letrozole—Decreased appetite—Dactinomycin—uterine cancer	0.000148	0.000838	CcSEcCtD
Letrozole—Dysgeusia—Etoposide—uterine cancer	0.000148	0.000837	CcSEcCtD
Letrozole—Fatigue—Dactinomycin—uterine cancer	0.000147	0.000831	CcSEcCtD
Letrozole—Back pain—Etoposide—uterine cancer	0.000146	0.000827	CcSEcCtD
Letrozole—Pain—Dactinomycin—uterine cancer	0.000145	0.000824	CcSEcCtD
Letrozole—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000144	0.000817	CcSEcCtD
Letrozole—Cardiac failure—Epirubicin—uterine cancer	0.000144	0.000815	CcSEcCtD
Letrozole—CYP19A1—Ovarian Infertility Genes—CDKN1B—uterine cancer	0.000143	0.0111	CbGpPWpGaD
Letrozole—Cerebrovascular accident—Epirubicin—uterine cancer	0.000143	0.000812	CcSEcCtD
Letrozole—Lethargy—Epirubicin—uterine cancer	0.000143	0.000812	CcSEcCtD
Letrozole—Nausea—Progesterone—uterine cancer	0.000143	0.00081	CcSEcCtD
Letrozole—Pain in extremity—Epirubicin—uterine cancer	0.00014	0.000796	CcSEcCtD
Letrozole—Feeling abnormal—Dactinomycin—uterine cancer	0.00014	0.000794	CcSEcCtD
Letrozole—Ill-defined disorder—Etoposide—uterine cancer	0.00014	0.000793	CcSEcCtD
Letrozole—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000139	0.000788	CcSEcCtD
Letrozole—Hot flush—Doxorubicin—uterine cancer	0.000139	0.000787	CcSEcCtD
Letrozole—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000139	0.000786	CcSEcCtD
Letrozole—Increased appetite—Doxorubicin—uterine cancer	0.000138	0.000784	CcSEcCtD
Letrozole—Menopausal symptoms—Doxorubicin—uterine cancer	0.000138	0.00078	CcSEcCtD
Letrozole—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000137	0.000779	CcSEcCtD
Letrozole—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000137	0.000779	CcSEcCtD
Letrozole—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000137	0.000774	CcSEcCtD
Letrozole—Malaise—Etoposide—uterine cancer	0.000136	0.000771	CcSEcCtD
Letrozole—Vertigo—Etoposide—uterine cancer	0.000136	0.000768	CcSEcCtD
Letrozole—CYP19A1—Metapathway biotransformation—AKR1C1—uterine cancer	0.000135	0.0105	CbGpPWpGaD
Letrozole—Leukopenia—Etoposide—uterine cancer	0.000135	0.000765	CcSEcCtD
Letrozole—Abdominal pain—Dactinomycin—uterine cancer	0.000134	0.000762	CcSEcCtD
Letrozole—Body temperature increased—Dactinomycin—uterine cancer	0.000134	0.000762	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—MSH2—uterine cancer	0.000134	0.0104	CbGpPWpGaD
Letrozole—Cardiac failure—Doxorubicin—uterine cancer	0.000133	0.000755	CcSEcCtD
Letrozole—Lethargy—Doxorubicin—uterine cancer	0.000133	0.000751	CcSEcCtD
Letrozole—Cerebrovascular accident—Doxorubicin—uterine cancer	0.000133	0.000751	CcSEcCtD
Letrozole—Cough—Etoposide—uterine cancer	0.000132	0.000746	CcSEcCtD
Letrozole—Hypertension—Etoposide—uterine cancer	0.00013	0.000738	CcSEcCtD
Letrozole—Pain in extremity—Doxorubicin—uterine cancer	0.00013	0.000736	CcSEcCtD
Letrozole—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00013	0.000734	CcSEcCtD
Letrozole—Dry skin—Epirubicin—uterine cancer	0.000129	0.000729	CcSEcCtD
Letrozole—Chest pain—Etoposide—uterine cancer	0.000128	0.000728	CcSEcCtD
Letrozole—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000128	0.000723	CcSEcCtD
Letrozole—Discomfort—Etoposide—uterine cancer	0.000127	0.000719	CcSEcCtD
Letrozole—Breast disorder—Epirubicin—uterine cancer	0.000127	0.000719	CcSEcCtD
Letrozole—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000126	0.000717	CcSEcCtD
Letrozole—CYP2A6—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000123	0.00958	CbGpPWpGaD
Letrozole—Anaphylactic shock—Etoposide—uterine cancer	0.000123	0.000698	CcSEcCtD
Letrozole—Infection—Etoposide—uterine cancer	0.000122	0.000693	CcSEcCtD
Letrozole—Asthenia—Dactinomycin—uterine cancer	0.000122	0.000692	CcSEcCtD
Letrozole—Influenza—Epirubicin—uterine cancer	0.000121	0.000688	CcSEcCtD
Letrozole—Tachycardia—Etoposide—uterine cancer	0.00012	0.000681	CcSEcCtD
Letrozole—Skin disorder—Etoposide—uterine cancer	0.00012	0.000678	CcSEcCtD
Letrozole—Dry skin—Doxorubicin—uterine cancer	0.000119	0.000675	CcSEcCtD
Letrozole—Hyperhidrosis—Etoposide—uterine cancer	0.000119	0.000675	CcSEcCtD
Letrozole—CYP19A1—Metapathway biotransformation—GPX3—uterine cancer	0.000119	0.00923	CbGpPWpGaD
Letrozole—Angina pectoris—Epirubicin—uterine cancer	0.000118	0.00067	CcSEcCtD
Letrozole—Breast disorder—Doxorubicin—uterine cancer	0.000117	0.000665	CcSEcCtD
Letrozole—Anorexia—Etoposide—uterine cancer	0.000117	0.000665	CcSEcCtD
Letrozole—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000117	0.000663	CcSEcCtD
Letrozole—Diarrhoea—Dactinomycin—uterine cancer	0.000116	0.00066	CcSEcCtD
Letrozole—CYP2A6—NRF2 pathway—NFE2L2—uterine cancer	0.000115	0.0089	CbGpPWpGaD
Letrozole—Influenza—Doxorubicin—uterine cancer	0.000112	0.000636	CcSEcCtD
Letrozole—Pollakiuria—Epirubicin—uterine cancer	0.000112	0.000635	CcSEcCtD
Letrozole—CYP19A1—Biological oxidations—CYP11A1—uterine cancer	0.000112	0.00869	CbGpPWpGaD
Letrozole—Paraesthesia—Etoposide—uterine cancer	0.000111	0.000627	CcSEcCtD
Letrozole—Weight increased—Epirubicin—uterine cancer	0.00011	0.000626	CcSEcCtD
Letrozole—CYP19A1—Metapathway biotransformation—CYP11A1—uterine cancer	0.00011	0.00857	CbGpPWpGaD
Letrozole—Weight decreased—Epirubicin—uterine cancer	0.00011	0.000622	CcSEcCtD
Letrozole—Dyspnoea—Etoposide—uterine cancer	0.00011	0.000622	CcSEcCtD
Letrozole—Somnolence—Etoposide—uterine cancer	0.000109	0.00062	CcSEcCtD
Letrozole—Angina pectoris—Doxorubicin—uterine cancer	0.000109	0.00062	CcSEcCtD
Letrozole—CYP2A6—NRF2 pathway—GPX3—uterine cancer	0.000109	0.00849	CbGpPWpGaD
Letrozole—Infestation NOS—Epirubicin—uterine cancer	0.000108	0.000613	CcSEcCtD
Letrozole—Infestation—Epirubicin—uterine cancer	0.000108	0.000613	CcSEcCtD
Letrozole—Vomiting—Dactinomycin—uterine cancer	0.000108	0.000613	CcSEcCtD
Letrozole—Rash—Dactinomycin—uterine cancer	0.000107	0.000608	CcSEcCtD
Letrozole—Decreased appetite—Etoposide—uterine cancer	0.000107	0.000607	CcSEcCtD
Letrozole—Gastrointestinal disorder—Etoposide—uterine cancer	0.000106	0.000602	CcSEcCtD
Letrozole—Fatigue—Etoposide—uterine cancer	0.000106	0.000602	CcSEcCtD
Letrozole—Stomatitis—Epirubicin—uterine cancer	0.000105	0.000598	CcSEcCtD
Letrozole—Pain—Etoposide—uterine cancer	0.000105	0.000597	CcSEcCtD
Letrozole—Constipation—Etoposide—uterine cancer	0.000105	0.000597	CcSEcCtD
Letrozole—Urinary tract infection—Epirubicin—uterine cancer	0.000105	0.000596	CcSEcCtD
Letrozole—CYP19A1—Metapathway biotransformation—AKR1C3—uterine cancer	0.000104	0.00809	CbGpPWpGaD
Letrozole—Sweating—Epirubicin—uterine cancer	0.000104	0.000588	CcSEcCtD
Letrozole—Pollakiuria—Doxorubicin—uterine cancer	0.000104	0.000588	CcSEcCtD
Letrozole—Hepatobiliary disease—Epirubicin—uterine cancer	0.000102	0.00058	CcSEcCtD
Letrozole—Weight increased—Doxorubicin—uterine cancer	0.000102	0.000579	CcSEcCtD
Letrozole—Weight decreased—Doxorubicin—uterine cancer	0.000102	0.000576	CcSEcCtD
Letrozole—Feeling abnormal—Etoposide—uterine cancer	0.000101	0.000575	CcSEcCtD
Letrozole—Nausea—Dactinomycin—uterine cancer	0.000101	0.000573	CcSEcCtD
Letrozole—Gastrointestinal pain—Etoposide—uterine cancer	0.000101	0.000571	CcSEcCtD
Letrozole—Infestation—Doxorubicin—uterine cancer	0.0001	0.000567	CcSEcCtD
Letrozole—Infestation NOS—Doxorubicin—uterine cancer	0.0001	0.000567	CcSEcCtD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	9.92e-05	0.00771	CbGpPWpGaD
Letrozole—Urticaria—Etoposide—uterine cancer	9.78e-05	0.000554	CcSEcCtD
Letrozole—Haemoglobin—Epirubicin—uterine cancer	9.76e-05	0.000553	CcSEcCtD
Letrozole—Stomatitis—Doxorubicin—uterine cancer	9.76e-05	0.000553	CcSEcCtD
Letrozole—Abdominal pain—Etoposide—uterine cancer	9.73e-05	0.000552	CcSEcCtD
Letrozole—Body temperature increased—Etoposide—uterine cancer	9.73e-05	0.000552	CcSEcCtD
Letrozole—Urinary tract infection—Doxorubicin—uterine cancer	9.73e-05	0.000552	CcSEcCtD
Letrozole—Haemorrhage—Epirubicin—uterine cancer	9.71e-05	0.000551	CcSEcCtD
Letrozole—Hepatitis—Epirubicin—uterine cancer	9.71e-05	0.000551	CcSEcCtD
Letrozole—Hypoaesthesia—Epirubicin—uterine cancer	9.66e-05	0.000548	CcSEcCtD
Letrozole—Sweating—Doxorubicin—uterine cancer	9.6e-05	0.000544	CcSEcCtD
Letrozole—Urinary tract disorder—Epirubicin—uterine cancer	9.59e-05	0.000544	CcSEcCtD
Letrozole—Oedema peripheral—Epirubicin—uterine cancer	9.57e-05	0.000542	CcSEcCtD
Letrozole—Connective tissue disorder—Epirubicin—uterine cancer	9.54e-05	0.000541	CcSEcCtD
Letrozole—Urethral disorder—Epirubicin—uterine cancer	9.52e-05	0.00054	CcSEcCtD
Letrozole—Hepatobiliary disease—Doxorubicin—uterine cancer	9.47e-05	0.000537	CcSEcCtD
Letrozole—Erythema multiforme—Epirubicin—uterine cancer	9.18e-05	0.000521	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—STK11—uterine cancer	9.13e-05	0.00709	CbGpPWpGaD
Letrozole—Eye disorder—Epirubicin—uterine cancer	9.08e-05	0.000514	CcSEcCtD
Letrozole—Haemoglobin—Doxorubicin—uterine cancer	9.03e-05	0.000512	CcSEcCtD
Letrozole—Flushing—Epirubicin—uterine cancer	9.01e-05	0.000511	CcSEcCtD
Letrozole—Cardiac disorder—Epirubicin—uterine cancer	9.01e-05	0.000511	CcSEcCtD
Letrozole—Haemorrhage—Doxorubicin—uterine cancer	8.99e-05	0.000509	CcSEcCtD
Letrozole—Hepatitis—Doxorubicin—uterine cancer	8.99e-05	0.000509	CcSEcCtD
Letrozole—Hypoaesthesia—Doxorubicin—uterine cancer	8.94e-05	0.000507	CcSEcCtD
Letrozole—CYP2A6—Biological oxidations—CYP11A1—uterine cancer	8.9e-05	0.00692	CbGpPWpGaD
Letrozole—Urinary tract disorder—Doxorubicin—uterine cancer	8.87e-05	0.000503	CcSEcCtD
Letrozole—Oedema peripheral—Doxorubicin—uterine cancer	8.85e-05	0.000502	CcSEcCtD
Letrozole—Asthenia—Etoposide—uterine cancer	8.83e-05	0.000501	CcSEcCtD
Letrozole—Connective tissue disorder—Doxorubicin—uterine cancer	8.83e-05	0.000501	CcSEcCtD
Letrozole—Angiopathy—Epirubicin—uterine cancer	8.81e-05	0.000499	CcSEcCtD
Letrozole—Urethral disorder—Doxorubicin—uterine cancer	8.81e-05	0.000499	CcSEcCtD
Letrozole—Mediastinal disorder—Epirubicin—uterine cancer	8.75e-05	0.000496	CcSEcCtD
Letrozole—CYP19A1—FSH signaling pathway—AKT1—uterine cancer	8.72e-05	0.00677	CbGpPWpGaD
Letrozole—Pruritus—Etoposide—uterine cancer	8.71e-05	0.000494	CcSEcCtD
Letrozole—Alopecia—Epirubicin—uterine cancer	8.58e-05	0.000486	CcSEcCtD
Letrozole—Mental disorder—Epirubicin—uterine cancer	8.51e-05	0.000482	CcSEcCtD
Letrozole—Erythema multiforme—Doxorubicin—uterine cancer	8.5e-05	0.000482	CcSEcCtD
Letrozole—Malnutrition—Epirubicin—uterine cancer	8.45e-05	0.000479	CcSEcCtD
Letrozole—Diarrhoea—Etoposide—uterine cancer	8.42e-05	0.000477	CcSEcCtD
Letrozole—Eye disorder—Doxorubicin—uterine cancer	8.4e-05	0.000476	CcSEcCtD
Letrozole—Cardiac disorder—Doxorubicin—uterine cancer	8.34e-05	0.000473	CcSEcCtD
Letrozole—Flushing—Doxorubicin—uterine cancer	8.34e-05	0.000473	CcSEcCtD
Letrozole—Tension—Epirubicin—uterine cancer	8.3e-05	0.00047	CcSEcCtD
Letrozole—Dysgeusia—Epirubicin—uterine cancer	8.28e-05	0.000469	CcSEcCtD
Letrozole—Nervousness—Epirubicin—uterine cancer	8.21e-05	0.000465	CcSEcCtD
Letrozole—Back pain—Epirubicin—uterine cancer	8.18e-05	0.000464	CcSEcCtD
Letrozole—Angiopathy—Doxorubicin—uterine cancer	8.15e-05	0.000462	CcSEcCtD
Letrozole—Dizziness—Etoposide—uterine cancer	8.14e-05	0.000461	CcSEcCtD
Letrozole—Mediastinal disorder—Doxorubicin—uterine cancer	8.1e-05	0.000459	CcSEcCtD
Letrozole—Vision blurred—Epirubicin—uterine cancer	7.97e-05	0.000452	CcSEcCtD
Letrozole—Alopecia—Doxorubicin—uterine cancer	7.94e-05	0.00045	CcSEcCtD
Letrozole—Mental disorder—Doxorubicin—uterine cancer	7.87e-05	0.000446	CcSEcCtD
Letrozole—Ill-defined disorder—Epirubicin—uterine cancer	7.84e-05	0.000445	CcSEcCtD
Letrozole—Vomiting—Etoposide—uterine cancer	7.83e-05	0.000444	CcSEcCtD
Letrozole—Malnutrition—Doxorubicin—uterine cancer	7.82e-05	0.000443	CcSEcCtD
Letrozole—Rash—Etoposide—uterine cancer	7.76e-05	0.00044	CcSEcCtD
Letrozole—Dermatitis—Etoposide—uterine cancer	7.75e-05	0.00044	CcSEcCtD
Letrozole—Headache—Etoposide—uterine cancer	7.71e-05	0.000437	CcSEcCtD
Letrozole—Tension—Doxorubicin—uterine cancer	7.68e-05	0.000435	CcSEcCtD
Letrozole—Dysgeusia—Doxorubicin—uterine cancer	7.66e-05	0.000434	CcSEcCtD
Letrozole—Malaise—Epirubicin—uterine cancer	7.62e-05	0.000432	CcSEcCtD
Letrozole—Nervousness—Doxorubicin—uterine cancer	7.6e-05	0.000431	CcSEcCtD
Letrozole—Vertigo—Epirubicin—uterine cancer	7.6e-05	0.000431	CcSEcCtD
Letrozole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	7.58e-05	0.00589	CbGpPWpGaD
Letrozole—Leukopenia—Epirubicin—uterine cancer	7.57e-05	0.000429	CcSEcCtD
Letrozole—Back pain—Doxorubicin—uterine cancer	7.57e-05	0.000429	CcSEcCtD
Letrozole—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	7.48e-05	0.00581	CbGpPWpGaD
Letrozole—Palpitations—Epirubicin—uterine cancer	7.47e-05	0.000424	CcSEcCtD
Letrozole—Cough—Epirubicin—uterine cancer	7.38e-05	0.000418	CcSEcCtD
Letrozole—Vision blurred—Doxorubicin—uterine cancer	7.37e-05	0.000418	CcSEcCtD
Letrozole—Nausea—Etoposide—uterine cancer	7.31e-05	0.000414	CcSEcCtD
Letrozole—Hypertension—Epirubicin—uterine cancer	7.3e-05	0.000414	CcSEcCtD
Letrozole—Ill-defined disorder—Doxorubicin—uterine cancer	7.26e-05	0.000411	CcSEcCtD
Letrozole—Arthralgia—Epirubicin—uterine cancer	7.2e-05	0.000408	CcSEcCtD
Letrozole—Chest pain—Epirubicin—uterine cancer	7.2e-05	0.000408	CcSEcCtD
Letrozole—Myalgia—Epirubicin—uterine cancer	7.2e-05	0.000408	CcSEcCtD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	7.18e-05	0.00558	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	7.18e-05	0.00558	CbGpPWpGaD
Letrozole—Anxiety—Epirubicin—uterine cancer	7.17e-05	0.000407	CcSEcCtD
Letrozole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	7.15e-05	0.000405	CcSEcCtD
Letrozole—Discomfort—Epirubicin—uterine cancer	7.11e-05	0.000403	CcSEcCtD
Letrozole—Malaise—Doxorubicin—uterine cancer	7.05e-05	0.0004	CcSEcCtD
Letrozole—Dry mouth—Epirubicin—uterine cancer	7.04e-05	0.000399	CcSEcCtD
Letrozole—Vertigo—Doxorubicin—uterine cancer	7.03e-05	0.000398	CcSEcCtD
Letrozole—Leukopenia—Doxorubicin—uterine cancer	7e-05	0.000397	CcSEcCtD
Letrozole—CYP2A6—Fluoropyrimidine Activity—TP53—uterine cancer	7e-05	0.00544	CbGpPWpGaD
Letrozole—Palpitations—Doxorubicin—uterine cancer	6.91e-05	0.000392	CcSEcCtD
Letrozole—Anaphylactic shock—Epirubicin—uterine cancer	6.9e-05	0.000391	CcSEcCtD
Letrozole—Oedema—Epirubicin—uterine cancer	6.9e-05	0.000391	CcSEcCtD
Letrozole—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	6.89e-05	0.00536	CbGpPWpGaD
Letrozole—Infection—Epirubicin—uterine cancer	6.85e-05	0.000389	CcSEcCtD
Letrozole—Cough—Doxorubicin—uterine cancer	6.83e-05	0.000387	CcSEcCtD
Letrozole—Nervous system disorder—Epirubicin—uterine cancer	6.77e-05	0.000384	CcSEcCtD
Letrozole—Hypertension—Doxorubicin—uterine cancer	6.75e-05	0.000383	CcSEcCtD
Letrozole—Tachycardia—Epirubicin—uterine cancer	6.73e-05	0.000382	CcSEcCtD
Letrozole—Skin disorder—Epirubicin—uterine cancer	6.7e-05	0.00038	CcSEcCtD
Letrozole—Hyperhidrosis—Epirubicin—uterine cancer	6.67e-05	0.000378	CcSEcCtD
Letrozole—Arthralgia—Doxorubicin—uterine cancer	6.66e-05	0.000378	CcSEcCtD
Letrozole—Chest pain—Doxorubicin—uterine cancer	6.66e-05	0.000378	CcSEcCtD
Letrozole—Myalgia—Doxorubicin—uterine cancer	6.66e-05	0.000378	CcSEcCtD
Letrozole—Anxiety—Doxorubicin—uterine cancer	6.64e-05	0.000376	CcSEcCtD
Letrozole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	6.61e-05	0.000375	CcSEcCtD
Letrozole—Discomfort—Doxorubicin—uterine cancer	6.58e-05	0.000373	CcSEcCtD
Letrozole—Anorexia—Epirubicin—uterine cancer	6.58e-05	0.000373	CcSEcCtD
Letrozole—CYP2A6—Biological oxidations—CYP19A1—uterine cancer	6.55e-05	0.00509	CbGpPWpGaD
Letrozole—Dry mouth—Doxorubicin—uterine cancer	6.51e-05	0.000369	CcSEcCtD
Letrozole—Anaphylactic shock—Doxorubicin—uterine cancer	6.38e-05	0.000362	CcSEcCtD
Letrozole—Oedema—Doxorubicin—uterine cancer	6.38e-05	0.000362	CcSEcCtD
Letrozole—Infection—Doxorubicin—uterine cancer	6.34e-05	0.00036	CcSEcCtD
Letrozole—Musculoskeletal discomfort—Epirubicin—uterine cancer	6.29e-05	0.000356	CcSEcCtD
Letrozole—Nervous system disorder—Doxorubicin—uterine cancer	6.26e-05	0.000355	CcSEcCtD
Letrozole—Insomnia—Epirubicin—uterine cancer	6.24e-05	0.000354	CcSEcCtD
Letrozole—Tachycardia—Doxorubicin—uterine cancer	6.23e-05	0.000353	CcSEcCtD
Letrozole—Skin disorder—Doxorubicin—uterine cancer	6.2e-05	0.000352	CcSEcCtD
Letrozole—Paraesthesia—Epirubicin—uterine cancer	6.2e-05	0.000351	CcSEcCtD
Letrozole—Hyperhidrosis—Doxorubicin—uterine cancer	6.17e-05	0.00035	CcSEcCtD
Letrozole—Dyspnoea—Epirubicin—uterine cancer	6.15e-05	0.000349	CcSEcCtD
Letrozole—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	6.14e-05	0.00477	CbGpPWpGaD
Letrozole—Somnolence—Epirubicin—uterine cancer	6.13e-05	0.000348	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—ESR1—uterine cancer	6.1e-05	0.00474	CbGpPWpGaD
Letrozole—Anorexia—Doxorubicin—uterine cancer	6.09e-05	0.000345	CcSEcCtD
Letrozole—Dyspepsia—Epirubicin—uterine cancer	6.07e-05	0.000344	CcSEcCtD
Letrozole—Decreased appetite—Epirubicin—uterine cancer	6e-05	0.00034	CcSEcCtD
Letrozole—Gastrointestinal disorder—Epirubicin—uterine cancer	5.96e-05	0.000338	CcSEcCtD
Letrozole—Fatigue—Epirubicin—uterine cancer	5.95e-05	0.000337	CcSEcCtD
Letrozole—Pain—Epirubicin—uterine cancer	5.9e-05	0.000334	CcSEcCtD
Letrozole—Constipation—Epirubicin—uterine cancer	5.9e-05	0.000334	CcSEcCtD
Letrozole—Musculoskeletal discomfort—Doxorubicin—uterine cancer	5.82e-05	0.00033	CcSEcCtD
Letrozole—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	5.79e-05	0.0045	CbGpPWpGaD
Letrozole—Insomnia—Doxorubicin—uterine cancer	5.77e-05	0.000327	CcSEcCtD
Letrozole—Paraesthesia—Doxorubicin—uterine cancer	5.73e-05	0.000325	CcSEcCtD
Letrozole—Dyspnoea—Doxorubicin—uterine cancer	5.69e-05	0.000323	CcSEcCtD
Letrozole—Feeling abnormal—Epirubicin—uterine cancer	5.69e-05	0.000322	CcSEcCtD
Letrozole—Somnolence—Doxorubicin—uterine cancer	5.68e-05	0.000322	CcSEcCtD
Letrozole—Gastrointestinal pain—Epirubicin—uterine cancer	5.64e-05	0.00032	CcSEcCtD
Letrozole—Dyspepsia—Doxorubicin—uterine cancer	5.62e-05	0.000319	CcSEcCtD
Letrozole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	5.57e-05	0.00433	CbGpPWpGaD
Letrozole—Decreased appetite—Doxorubicin—uterine cancer	5.55e-05	0.000315	CcSEcCtD
Letrozole—Gastrointestinal disorder—Doxorubicin—uterine cancer	5.51e-05	0.000312	CcSEcCtD
Letrozole—Fatigue—Doxorubicin—uterine cancer	5.5e-05	0.000312	CcSEcCtD
Letrozole—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	5.5e-05	0.00427	CbGpPWpGaD
Letrozole—Urticaria—Epirubicin—uterine cancer	5.48e-05	0.000311	CcSEcCtD
Letrozole—Pain—Doxorubicin—uterine cancer	5.46e-05	0.000309	CcSEcCtD
Letrozole—Constipation—Doxorubicin—uterine cancer	5.46e-05	0.000309	CcSEcCtD
Letrozole—Body temperature increased—Epirubicin—uterine cancer	5.45e-05	0.000309	CcSEcCtD
Letrozole—Abdominal pain—Epirubicin—uterine cancer	5.45e-05	0.000309	CcSEcCtD
Letrozole—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	5.38e-05	0.00418	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—CDH1—uterine cancer	5.3e-05	0.00412	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	5.27e-05	0.00409	CbGpPWpGaD
Letrozole—Feeling abnormal—Doxorubicin—uterine cancer	5.26e-05	0.000298	CcSEcCtD
Letrozole—Gastrointestinal pain—Doxorubicin—uterine cancer	5.22e-05	0.000296	CcSEcCtD
Letrozole—Urticaria—Doxorubicin—uterine cancer	5.07e-05	0.000288	CcSEcCtD
Letrozole—Abdominal pain—Doxorubicin—uterine cancer	5.05e-05	0.000286	CcSEcCtD
Letrozole—Body temperature increased—Doxorubicin—uterine cancer	5.05e-05	0.000286	CcSEcCtD
Letrozole—Asthenia—Epirubicin—uterine cancer	4.95e-05	0.000281	CcSEcCtD
Letrozole—Pruritus—Epirubicin—uterine cancer	4.88e-05	0.000277	CcSEcCtD
Letrozole—Diarrhoea—Epirubicin—uterine cancer	4.72e-05	0.000268	CcSEcCtD
Letrozole—Asthenia—Doxorubicin—uterine cancer	4.58e-05	0.00026	CcSEcCtD
Letrozole—Dizziness—Epirubicin—uterine cancer	4.56e-05	0.000259	CcSEcCtD
Letrozole—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	4.52e-05	0.00351	CbGpPWpGaD
Letrozole—Pruritus—Doxorubicin—uterine cancer	4.52e-05	0.000256	CcSEcCtD
Letrozole—CYP19A1—Metabolism—SRD5A2—uterine cancer	4.42e-05	0.00343	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—NDUFB11—uterine cancer	4.42e-05	0.00343	CbGpPWpGaD
Letrozole—Vomiting—Epirubicin—uterine cancer	4.39e-05	0.000249	CcSEcCtD
Letrozole—Diarrhoea—Doxorubicin—uterine cancer	4.37e-05	0.000248	CcSEcCtD
Letrozole—Rash—Epirubicin—uterine cancer	4.35e-05	0.000247	CcSEcCtD
Letrozole—Dermatitis—Epirubicin—uterine cancer	4.35e-05	0.000246	CcSEcCtD
Letrozole—Headache—Epirubicin—uterine cancer	4.32e-05	0.000245	CcSEcCtD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.29e-05	0.00334	CbGpPWpGaD
Letrozole—Dizziness—Doxorubicin—uterine cancer	4.22e-05	0.000239	CcSEcCtD
Letrozole—Nausea—Epirubicin—uterine cancer	4.1e-05	0.000232	CcSEcCtD
Letrozole—Vomiting—Doxorubicin—uterine cancer	4.06e-05	0.00023	CcSEcCtD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4.05e-05	0.00315	CbGpPWpGaD
Letrozole—Rash—Doxorubicin—uterine cancer	4.03e-05	0.000228	CcSEcCtD
Letrozole—Dermatitis—Doxorubicin—uterine cancer	4.02e-05	0.000228	CcSEcCtD
Letrozole—Headache—Doxorubicin—uterine cancer	4e-05	0.000227	CcSEcCtD
Letrozole—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	3.95e-05	0.00307	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	3.92e-05	0.00304	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—PTEN—uterine cancer	3.82e-05	0.00297	CbGpPWpGaD
Letrozole—Nausea—Doxorubicin—uterine cancer	3.79e-05	0.000215	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—EP300—uterine cancer	3.64e-05	0.00283	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—SRD5A2—uterine cancer	3.52e-05	0.00273	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—NDUFB11—uterine cancer	3.52e-05	0.00273	CbGpPWpGaD
Letrozole—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	3.47e-05	0.00269	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	3.45e-05	0.00268	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	3.26e-05	0.00254	CbGpPWpGaD
Letrozole—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	3.22e-05	0.0025	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—AKR1B1—uterine cancer	3.2e-05	0.00248	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—STAR—uterine cancer	3.2e-05	0.00248	CbGpPWpGaD
Letrozole—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	3.04e-05	0.00236	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—KRAS—uterine cancer	2.93e-05	0.00228	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—TP53—uterine cancer	2.6e-05	0.00202	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—AKR1B1—uterine cancer	2.54e-05	0.00198	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—STAR—uterine cancer	2.54e-05	0.00198	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—POLD1—uterine cancer	2.51e-05	0.00195	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	2.4e-05	0.00187	CbGpPWpGaD
Letrozole—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	2.37e-05	0.00184	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—AKR1C1—uterine cancer	2.35e-05	0.00182	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—AKT1—uterine cancer	2.2e-05	0.00171	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—RRM2—uterine cancer	2.09e-05	0.00162	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—DCN—uterine cancer	2.03e-05	0.00158	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—POLD1—uterine cancer	2e-05	0.00155	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—CYP11A1—uterine cancer	1.91e-05	0.00149	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—AKR1C1—uterine cancer	1.87e-05	0.00145	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—AKR1C3—uterine cancer	1.81e-05	0.0014	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—RRM2—uterine cancer	1.66e-05	0.00129	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—DCN—uterine cancer	1.62e-05	0.00126	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—CYP11A1—uterine cancer	1.52e-05	0.00118	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—AKR1C3—uterine cancer	1.44e-05	0.00112	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—STK11—uterine cancer	1.41e-05	0.00109	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.32e-05	0.00103	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.29e-05	0.001	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.29e-05	0.001	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.26e-05	0.000979	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—STK11—uterine cancer	1.12e-05	0.00087	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—CYP19A1—uterine cancer	1.12e-05	0.00087	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—MTHFR—uterine cancer	1.06e-05	0.000821	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—AKR1B1—uterine cancer	9.33e-06	0.000725	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—STAR—uterine cancer	9.33e-06	0.000725	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	9.32e-06	0.000724	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—MTHFR—uterine cancer	8.41e-06	0.000654	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—POLD1—uterine cancer	7.32e-06	0.000569	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—AKR1C1—uterine cancer	6.84e-06	0.000532	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—RRM2—uterine cancer	6.1e-06	0.000474	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—DCN—uterine cancer	5.92e-06	0.00046	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—PTEN—uterine cancer	5.88e-06	0.000457	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—EP300—uterine cancer	5.61e-06	0.000436	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—CYP11A1—uterine cancer	5.58e-06	0.000434	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—AKR1C3—uterine cancer	5.27e-06	0.000409	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—PTEN—uterine cancer	4.68e-06	0.000364	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—EP300—uterine cancer	4.46e-06	0.000347	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—PIK3CA—uterine cancer	4.15e-06	0.000322	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—STK11—uterine cancer	4.11e-06	0.000319	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.11e-06	0.000319	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—AKT1—uterine cancer	3.39e-06	0.000263	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—PIK3CA—uterine cancer	3.3e-06	0.000257	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—MTHFR—uterine cancer	3.08e-06	0.00024	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—AKT1—uterine cancer	2.7e-06	0.00021	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—PTEN—uterine cancer	1.72e-06	0.000133	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—EP300—uterine cancer	1.64e-06	0.000127	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.21e-06	9.41e-05	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—AKT1—uterine cancer	9.89e-07	7.69e-05	CbGpPWpGaD
